ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Clinical trials for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell therapy targets tough autoimmune conditions
Disease control Recruiting nowThis early-phase study tests a new cell treatment called YTS109 in 18 adults with severe autoimmune diseases like lupus and vasculitis that have not responded to standard therapies. Participants receive a single infusion of these specially engineered cells. The main goal is to ch…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 01:37 UTC
-
New hope for ANCA vasculitis: experimental drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new drug called tarperprumig for people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The trial will include 75 adults with newly diagnosed or relapsing disease. Researchers aim to see if the drug is safe and can…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 01:33 UTC
-
New cell therapy trial aims to tame tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and Sjogren's syndrome. The main goal is to check if the treatment is safe, and also to see if it helps control the disease. Participants receive a singl…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Engineered immune cells take on lupus and arthritis in new trial
Disease control Recruiting nowThis early-stage study is testing a new treatment called anti-CD19/BCMA universal CAR-T cells for people with severe autoimmune diseases like lupus, scleroderma, and rheumatoid arthritis that haven't responded to standard therapies. The treatment uses specially engineered immune …
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New cell shot aims to tame Out-of-Control immune attacks
Disease control Recruiting nowThis early study tests a new cell treatment called YTS109 in 18 adults with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard care. Participants get a single infusion of these specially designed cells. The main goal is to see if the treatme…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New cell therapy aims to tame tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in about 18 adults with autoimmune diseases like lupus that have not responded to standard therapies. Participants receive a single infusion of these specially designed cells. The main goal is to check safety and see…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New hope for patients with Treatment-Resistant autoimmune disease
Disease control Recruiting nowThis study aims to find the best treatment for patients with granulomatosis with polyangiitis (GPA), a serious autoimmune disease, when standard therapies have failed. It will compare three different drug strategies involving combinations of medications like rituximab, tocilizuma…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Apr 07, 2026 14:38 UTC